Skip to content

Thebaine Urine Testing

Clinical Feasibility of Thebaine Urine Mass Spectrometry Drug Testing

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07192887
Enrollment
20
Registered
2025-09-25
Start date
2025-05-07
Completion date
2027-03-31
Last updated
2025-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urine Specimen Collection

Brief summary

To develop and validate a urine drug screen to detect thebaine.

Interventions

None listed

Sponsors

Children's Hospital Medical Center, Cincinnati
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Male or female * Ages 18-65 * Healthy

Exclusion criteria

* Allergy to poppy seeds, or any of the related food stuffs used in the study * Celiac disease or gluten sensitivity * Ongoing or opioid use in the past 6 months * History of renal or hepatic disease or dysfunction * Inability or unwillingness to give repeated urine specimens * Unwillingness to refrain from eating poppy seed-containing products during the two-day course of the study * Non-English speakers (due to study materials being in English) * BMI greater than 30 * Antibiotic use in the previous 2 months * Recent ingestion of poppy seeds from the previous 7 days

Design outcomes

Primary

MeasureTime frameDescription
Validate thebaine urine screenEnrollment to 48 hours after enrollmentValidate a liquid chromatography-tandem mass spectrometry method to detect thebaine in urine

Countries

United States

Contacts

Primary ContactCharlotte Walter, MD
charlotte.walter@cchmc.org513-636-4408

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026